MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

25.14 5.81

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.89

Максимум

25.44

Ключови измерители
By Trading Economics
Приходи	-7.3M -68M
Продажби	23M 68M
Марж на печалбата	-99.318
Служители	298
EBITDA	42M -15M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+65.66% upside

Дивиденти
By Dow Jones
Следващи печалби	4.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	253M 2B
Предишно отваряне	19.33
Предишно затваряне	25.14

Настроения в новините

By Acuity

50%

154 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.04.2026 г., 04:27 ч. UTC

Значими събития в новините

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2026 г., 18:30 ч. UTC

Значими събития в новините

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3.04.2026 г., 18:14 ч. UTC

Пазарно говорене

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3.04.2026 г., 17:50 ч. UTC

Пазарно говорене

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3.04.2026 г., 17:44 ч. UTC

Придобивния, сливания и поглъщания

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3.04.2026 г., 16:50 ч. UTC

Значими събития в новините

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2026 г., 16:12 ч. UTC

Печалби

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3.04.2026 г., 15:56 ч. UTC

Пазарно говорене

Значими събития в новините

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3.04.2026 г., 15:56 ч. UTC

Пазарно говорене

Значими събития в новините

Global Equities Roundup: Market Talk

3.04.2026 г., 15:56 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

3.04.2026 г., 15:20 ч. UTC

Значими събития в новините

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3.04.2026 г., 15:08 ч. UTC

Придобивния, сливания и поглъщания

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3.04.2026 г., 14:11 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3.04.2026 г., 12:56 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2026 г., 08:01 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.04.2026 г., 08:01 ч. UTC

Пазарно говорене

Meituan's Profitability Likely to Improve This Year -- Market Talk

3.04.2026 г., 07:45 ч. UTC

Пазарно говорене

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3.04.2026 г., 06:17 ч. UTC

Пазарно говорене

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3.04.2026 г., 06:17 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.04.2026 г., 04:33 ч. UTC

Пазарно говорене

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3.04.2026 г., 04:33 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.04.2026 г., 04:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

3.04.2026 г., 04:01 ч. UTC

Пазарно говорене

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3.04.2026 г., 02:01 ч. UTC

Пазарно говорене

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3.04.2026 г., 01:59 ч. UTC

Пазарно говорене

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3.04.2026 г., 01:44 ч. UTC

Пазарно говорене

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3.04.2026 г., 01:22 ч. UTC

Пазарно говорене

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

65.66% нагоре

12-месечна прогноза

Среден 39.56 USD 65.66%

Висок 57 USD

Нисък 28 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

154 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.